{
  "schemaVersion": "peptidescanner-public-data/v1",
  "canonicalUrl": "https://peptidescanner.com/public-data/v1/index.json",
  "publisher": {
    "name": "GoodSir Labs",
    "url": "https://peptidescanner.com/about/"
  },
  "release": {
    "label": "Beta · 29 Jul 2026",
    "reviewedAt": "2026-07-29",
    "sourceSchemaVersion": "public-beta-content/v1"
  },
  "coverage": {
    "scope": "Selected public U.S. label, trial, regulatory, and safety records.",
    "limitations": "Coverage is selective, not continuous or exhaustive, and is not medical advice.",
    "methodologyUrl": "https://peptidescanner.com/methodology/",
    "correctionsUrl": "https://peptidescanner.com/corrections/"
  },
  "profiles": [
    {
      "slug": "abaloparatide",
      "canonicalUrl": "https://peptidescanner.com/peptides/abaloparatide/",
      "name": "Abaloparatide",
      "relatedNames": [
        "Tymlos"
      ],
      "topic": "Bone",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A parathyroid hormone-related peptide analogue. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Abaloparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=18"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/abaloparatide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/abaloparatide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "afamelanotide",
      "canonicalUrl": "https://peptidescanner.com/peptides/afamelanotide/",
      "name": "Afamelanotide",
      "relatedNames": [
        "Scenesse"
      ],
      "topic": "Dermatology",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A melanocortin analogue. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Afamelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=94f53286-11dd-7fbb-e053-2a95a90a7c48&version=11"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/afamelanotide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/afamelanotide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "amycretin",
      "canonicalUrl": "https://peptidescanner.com/peptides/amycretin/",
      "name": "Amycretin",
      "relatedNames": [],
      "topic": "Metabolic",
      "status": "investigational",
      "statusLabel": "Investigational",
      "summary": "An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.",
      "evidenceNote": "ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.",
      "organizations": [
        {
          "name": "Novo Nordisk A/S",
          "sourceIds": [
            "ctg-nct06049329-v6"
          ]
        }
      ],
      "trialIds": [
        "NCT06049329"
      ],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "ctg-nct06049329-v6"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "ctg-nct06049329-v6"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT06049329?a=6&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/amycretin/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/amycretin/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "ctg-nct06049329-v6"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "bpc-157",
      "canonicalUrl": "https://peptidescanner.com/peptides/bpc-157/",
      "name": "BPC-157",
      "relatedNames": [
        "Body protection compound 157"
      ],
      "topic": "Unapproved and safety records",
      "status": "unapproved",
      "statusLabel": "Not an FDA-approved drug",
      "summary": "A research peptide represented by FDA compounding-review material and one selected trial-registry record.",
      "evidenceNote": "FDA presented BPC-157 briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding and FDA's final determination remains pending; the cited trial registration also does not establish safety or effectiveness.",
      "organizations": [
        {
          "name": "U.S. Food and Drug Administration",
          "sourceIds": [
            "fda-bpc-157-briefing",
            "fda-pcac-peptide-meeting-2026"
          ]
        },
        {
          "name": "Hudson Biotech",
          "sourceIds": [
            "ctg-nct07437547-v1"
          ]
        }
      ],
      "trialIds": [
        "NCT07437547"
      ],
      "version": 2,
      "publishedAt": "2026-07-29",
      "correction": {
        "state": "updated",
        "notice": "We added the July 2026 FDA advisory-committee meeting context and clarified that both the committee process and the selected trial record have limited implications.",
        "publishedAt": "2026-07-29",
        "sourceIds": [
          "fda-bpc-157-briefing",
          "fda-pcac-peptide-meeting-2026"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "fda-bpc-157-briefing",
        "fda-bulk-peptide-risks",
        "ctg-nct07437547-v1",
        "fda-pcac-peptide-meeting-2026"
      ],
      "citations": [
        "https://www.fda.gov/media/193343/download",
        "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks",
        "https://clinicaltrials.gov/study/NCT07437547?a=1&tab=history",
        "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/bpc-157/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/bpc-157/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "updated",
            "notice": "We added the July 2026 FDA advisory-committee meeting context and clarified that both the committee process and the selected trial record have limited implications.",
            "publishedAt": "2026-07-29",
            "sourceIds": [
              "fda-bpc-157-briefing",
              "fda-pcac-peptide-meeting-2026"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "bremelanotide",
      "canonicalUrl": "https://peptidescanner.com/peptides/bremelanotide/",
      "name": "Bremelanotide",
      "relatedNames": [
        "Vyleesi",
        "PT-141"
      ],
      "topic": "Reproductive health",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A melanocortin receptor agonist peptide. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Bremelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1"
          ]
        }
      ],
      "trialIds": [],
      "version": 3,
      "publishedAt": "2026-07-29",
      "correction": {
        "state": "updated",
        "notice": "We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.",
        "publishedAt": "2026-07-29",
        "sourceIds": [
          "fda-bremelanotide-identity"
        ],
        "supersedesVersion": 2
      },
      "sourceIds": [
        "dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1",
        "fda-bremelanotide-identity"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf&version=1",
        "https://precision.fda.gov/uniisearch/srs/unii/PV2WI7495P"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/bremelanotide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/bremelanotide/versions/2/",
          "publishedAt": "2026-07-27",
          "supersededAt": "2026-07-29",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1"
            ],
            "supersedesVersion": 1
          }
        },
        {
          "version": 3,
          "canonicalUrl": "https://peptidescanner.com/peptides/bremelanotide/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "updated",
            "notice": "We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.",
            "publishedAt": "2026-07-29",
            "sourceIds": [
              "fda-bremelanotide-identity"
            ],
            "supersedesVersion": 2
          }
        }
      ]
    },
    {
      "slug": "cagrilintide",
      "canonicalUrl": "https://peptidescanner.com/peptides/cagrilintide/",
      "name": "Cagrilintide",
      "relatedNames": [
        "AM833"
      ],
      "topic": "Metabolic",
      "status": "investigational",
      "statusLabel": "Investigational",
      "summary": "A long-acting amylin analogue under study. This profile cites a recruiting ClinicalTrials.gov record.",
      "evidenceNote": "ClinicalTrials.gov lists a Novo Nordisk pediatric study as recruiting, updated July 17, 2026.",
      "organizations": [
        {
          "name": "Novo Nordisk A/S",
          "sourceIds": [
            "ctg-nct07253285-v5"
          ]
        }
      ],
      "trialIds": [
        "NCT07253285"
      ],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "ctg-nct07253285-v5"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "ctg-nct07253285-v5"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT07253285?a=5&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/cagrilintide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/cagrilintide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "ctg-nct07253285-v5"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "cjc-1295",
      "canonicalUrl": "https://peptidescanner.com/peptides/cjc-1295/",
      "name": "CJC-1295",
      "relatedNames": [
        "CJC-1295 DAC"
      ],
      "topic": "Unapproved and safety records",
      "status": "unapproved",
      "statusLabel": "Unapproved new drug in cited enforcement record",
      "summary": "A peptide named in FDA compounding-risk and DOJ enforcement records.",
      "evidenceNote": "FDA's compounding-risk page describes immunogenicity, impurity, and adverse-event concerns. A separate Justice Department release names CJC 1295 among unapproved new drugs distributed by the cited pharmacy.",
      "organizations": [
        {
          "name": "U.S. Food and Drug Administration",
          "sourceIds": [
            "fda-bulk-peptide-risks"
          ]
        }
      ],
      "trialIds": [],
      "version": 1,
      "publishedAt": "2026-07-22",
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "fda-bulk-peptide-risks",
        "doj-unapproved-peptide-enforcement"
      ],
      "citations": [
        "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks",
        "https://www.justice.gov/usao-edky/pr/nicholasville-compounding-pharmacy-and-its-owner-plead-guilty-unlawful-distribution"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/cjc-1295/",
          "publishedAt": "2026-07-22",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "dulaglutide",
      "canonicalUrl": "https://peptidescanner.com/peptides/dulaglutide/",
      "name": "Dulaglutide",
      "relatedNames": [
        "Trulicity"
      ],
      "topic": "Metabolic",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A GLP-1 receptor agonist. This profile cites a Trulicity label.",
      "evidenceNote": "The cited DailyMed label identifies Dulaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=463050bd-2b1c-40f5-b3c3-0a04bb433309&version=60"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/dulaglutide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/dulaglutide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "elamipretide",
      "canonicalUrl": "https://peptidescanner.com/peptides/elamipretide/",
      "name": "Elamipretide",
      "relatedNames": [
        "SS-31",
        "MTP-131"
      ],
      "topic": "Rare disease",
      "status": "investigational",
      "statusLabel": "Investigational",
      "summary": "A mitochondria-targeting peptide candidate. This profile cites a recruiting ClinicalTrials.gov study record.",
      "evidenceNote": "ClinicalTrials.gov lists the 4TAZPower study as recruiting, updated July 13, 2026.",
      "organizations": [
        {
          "name": "Stealth BioTherapeutics Inc.",
          "sourceIds": [
            "ctg-nct07531251-v4"
          ]
        }
      ],
      "trialIds": [
        "NCT07531251"
      ],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "ctg-nct07531251-v4"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "ctg-nct07531251-v4"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT07531251?a=4&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/elamipretide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/elamipretide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "ctg-nct07531251-v4"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "emideltide",
      "canonicalUrl": "https://peptidescanner.com/peptides/emideltide/",
      "name": "Emideltide",
      "relatedNames": [
        "DSIP"
      ],
      "topic": "Safety records",
      "status": "safety-review",
      "statusLabel": "FDA compounding safety review; final determination pending",
      "summary": "A peptide also called DSIP in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.",
      "evidenceNote": "FDA's emideltide briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.",
      "organizations": [
        {
          "name": "U.S. Food and Drug Administration",
          "sourceIds": [
            "fda-emideltide-briefing",
            "fda-pcac-peptide-meeting-2026"
          ]
        }
      ],
      "trialIds": [],
      "version": 1,
      "publishedAt": "2026-07-29",
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "fda-emideltide-briefing",
        "fda-pcac-peptide-meeting-2026"
      ],
      "citations": [
        "https://www.fda.gov/media/193344/download",
        "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/emideltide/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "epitalon",
      "canonicalUrl": "https://peptidescanner.com/peptides/epitalon/",
      "name": "Epitalon",
      "relatedNames": [],
      "topic": "Safety records",
      "status": "safety-review",
      "statusLabel": "FDA compounding safety review; final determination pending",
      "summary": "A synthetic tetrapeptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.",
      "evidenceNote": "FDA's Epitalon briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.",
      "organizations": [
        {
          "name": "U.S. Food and Drug Administration",
          "sourceIds": [
            "fda-epitalon-briefing",
            "fda-pcac-peptide-meeting-2026"
          ]
        }
      ],
      "trialIds": [],
      "version": 1,
      "publishedAt": "2026-07-29",
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "fda-epitalon-briefing",
        "fda-pcac-peptide-meeting-2026"
      ],
      "citations": [
        "https://www.fda.gov/media/193345/download",
        "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/epitalon/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "exenatide",
      "canonicalUrl": "https://peptidescanner.com/peptides/exenatide/",
      "name": "Exenatide",
      "relatedNames": [],
      "topic": "Metabolic",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A GLP-1 receptor agonist. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Exenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=e6cb5c8f-e97f-4a6a-95a4-939fd2393949&version=17"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/exenatide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/exenatide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "ghk-cu",
      "canonicalUrl": "https://peptidescanner.com/peptides/ghk-cu/",
      "name": "GHK-Cu",
      "relatedNames": [
        "Copper tripeptide-1",
        "GHK copper"
      ],
      "topic": "Safety records",
      "status": "safety-review",
      "statusLabel": "FDA compounding-list review for non-injectable routes",
      "summary": "A copper-binding peptide named in FDA's list of bulk substances under evaluation for non-injectable compounding.",
      "evidenceNote": "FDA lists GHK-Cu, except injectable routes, in Category 1 for bulk substances under evaluation. That listing does not establish FDA approval, safety, or effectiveness.",
      "organizations": [
        {
          "name": "U.S. Food and Drug Administration",
          "sourceIds": [
            "fda-ghk-cu-503a-2026"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-29",
      "correction": {
        "state": "updated",
        "notice": "We added FDA substance-identity aliases to improve search matching. The cited compounding-list status did not change.",
        "publishedAt": "2026-07-29",
        "sourceIds": [
          "fda-ghk-cu-identity"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "fda-ghk-cu-503a-2026",
        "fda-ghk-cu-identity"
      ],
      "citations": [
        "https://www.fda.gov/media/94155/download?attachment",
        "https://precision.fda.gov/uniisearch/srs/unii/6BJQ43T1I9"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/ghk-cu/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/ghk-cu/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "updated",
            "notice": "We added FDA substance-identity aliases to improve search matching. The cited compounding-list status did not change.",
            "publishedAt": "2026-07-29",
            "sourceIds": [
              "fda-ghk-cu-identity"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "glucagon",
      "canonicalUrl": "https://peptidescanner.com/peptides/glucagon/",
      "name": "Glucagon",
      "relatedNames": [
        "Gvoke VialDx"
      ],
      "topic": "Metabolic",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A peptide hormone. This profile cites a U.S. emergency-treatment label.",
      "evidenceNote": "The cited DailyMed label identifies Glucagon and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=359982a8-ec5c-4927-8c0f-89771e0f942b&version=2"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/glucagon/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/glucagon/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "insulin-glargine-aldy",
      "canonicalUrl": "https://peptidescanner.com/peptides/insulin-glargine-aldy/",
      "name": "Insulin glargine-aldy",
      "relatedNames": [
        "Langlara"
      ],
      "topic": "Metabolic",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A long-acting insulin analogue. This profile cites a U.S. prescription label.",
      "evidenceNote": "The cited DailyMed label identifies Insulin glargine-aldy and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=5328761e-59d3-ca7a-e063-6394a90ae810&version=5"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/insulin-glargine-aldy/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/insulin-glargine-aldy/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "ipamorelin",
      "canonicalUrl": "https://peptidescanner.com/peptides/ipamorelin/",
      "name": "Ipamorelin",
      "relatedNames": [
        "Ipamorelin acetate"
      ],
      "topic": "Unapproved and safety records",
      "status": "unapproved",
      "statusLabel": "Unapproved new drug in cited enforcement record",
      "summary": "A peptide named in FDA compounding-risk and DOJ enforcement records.",
      "evidenceNote": "FDA's compounding-risk page describes immunogenicity and characterization concerns. A separate Justice Department release names Ipamorelin among unapproved new drugs distributed by the cited pharmacy.",
      "organizations": [
        {
          "name": "U.S. Food and Drug Administration",
          "sourceIds": [
            "fda-bulk-peptide-risks"
          ]
        }
      ],
      "trialIds": [],
      "version": 1,
      "publishedAt": "2026-07-22",
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "fda-bulk-peptide-risks",
        "doj-unapproved-peptide-enforcement"
      ],
      "citations": [
        "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks",
        "https://www.justice.gov/usao-edky/pr/nicholasville-compounding-pharmacy-and-its-owner-plead-guilty-unlawful-distribution"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/ipamorelin/",
          "publishedAt": "2026-07-22",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "kpv",
      "canonicalUrl": "https://peptidescanner.com/peptides/kpv/",
      "name": "KPV",
      "relatedNames": [],
      "topic": "Safety records",
      "status": "safety-review",
      "statusLabel": "FDA compounding safety review; final determination pending",
      "summary": "A tripeptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.",
      "evidenceNote": "FDA's KPV briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.",
      "organizations": [
        {
          "name": "U.S. Food and Drug Administration",
          "sourceIds": [
            "fda-kpv-briefing",
            "fda-pcac-peptide-meeting-2026"
          ]
        }
      ],
      "trialIds": [],
      "version": 1,
      "publishedAt": "2026-07-29",
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "fda-kpv-briefing",
        "fda-pcac-peptide-meeting-2026"
      ],
      "citations": [
        "https://www.fda.gov/media/193346/download",
        "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/kpv/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "lanreotide",
      "canonicalUrl": "https://peptidescanner.com/peptides/lanreotide/",
      "name": "Lanreotide",
      "relatedNames": [
        "Lanreotide acetate"
      ],
      "topic": "Endocrine",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A somatostatin analogue. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Lanreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=2892b4c3-0329-4d29-97ff-3b45283bbab1&version=3"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/lanreotide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/lanreotide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "leuprolide",
      "canonicalUrl": "https://peptidescanner.com/peptides/leuprolide/",
      "name": "Leuprolide",
      "relatedNames": [
        "Leuprolide acetate"
      ],
      "topic": "Endocrine",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A GnRH agonist. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Leuprolide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4838c674-044e-46b2-81e7-c691b99d8fa5&version=10"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/leuprolide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/leuprolide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "linaclotide",
      "canonicalUrl": "https://peptidescanner.com/peptides/linaclotide/",
      "name": "Linaclotide",
      "relatedNames": [
        "Linzess"
      ],
      "topic": "Gastrointestinal",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A guanylate cyclase-C agonist peptide. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Linaclotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=09beda19-56d6-4a56-afdc-9a77b70b2ef3&version=39"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/linaclotide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/linaclotide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "liraglutide",
      "canonicalUrl": "https://peptidescanner.com/peptides/liraglutide/",
      "name": "Liraglutide",
      "relatedNames": [
        "Saxenda"
      ],
      "topic": "Metabolic",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A GLP-1 receptor agonist. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Liraglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6"
          ]
        }
      ],
      "trialIds": [],
      "version": 3,
      "publishedAt": "2026-07-29",
      "correction": {
        "state": "updated",
        "notice": "We added a product-name lookup term that the cited FDA label communication connects to liraglutide. The profile's status did not change.",
        "publishedAt": "2026-07-29",
        "sourceIds": [
          "fda-glp1-label-warning-request-2026"
        ],
        "supersedesVersion": 2
      },
      "sourceIds": [
        "dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6",
        "fda-glp1-label-warning-request-2026"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=22c86976-9657-4dd0-8fff-0c3f3f08357c&version=6",
        "https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/liraglutide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/liraglutide/versions/2/",
          "publishedAt": "2026-07-27",
          "supersededAt": "2026-07-29",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6"
            ],
            "supersedesVersion": 1
          }
        },
        {
          "version": 3,
          "canonicalUrl": "https://peptidescanner.com/peptides/liraglutide/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "updated",
            "notice": "We added a product-name lookup term that the cited FDA label communication connects to liraglutide. The profile's status did not change.",
            "publishedAt": "2026-07-29",
            "sourceIds": [
              "fda-glp1-label-warning-request-2026"
            ],
            "supersedesVersion": 2
          }
        }
      ]
    },
    {
      "slug": "lixisenatide",
      "canonicalUrl": "https://peptidescanner.com/peptides/lixisenatide/",
      "name": "Lixisenatide",
      "relatedNames": [
        "Soliqua 100/33"
      ],
      "topic": "Metabolic",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A GLP-1 receptor agonist component. This profile cites a U.S. combination-product label.",
      "evidenceNote": "The cited DailyMed label identifies Lixisenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=25"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/lixisenatide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/lixisenatide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "maridebart-cafraglutide",
      "canonicalUrl": "https://peptidescanner.com/peptides/maridebart-cafraglutide/",
      "name": "Maridebart cafraglutide",
      "relatedNames": [
        "MariTide",
        "AMG 133"
      ],
      "topic": "Metabolic",
      "status": "investigational",
      "statusLabel": "Investigational",
      "summary": "An antibody-peptide conjugate candidate. This profile cites a completed ClinicalTrials.gov study record.",
      "evidenceNote": "ClinicalTrials.gov lists an Amgen bioavailability study as completed, updated July 21, 2026.",
      "organizations": [
        {
          "name": "Amgen",
          "sourceIds": [
            "ctg-nct07717814-v1"
          ]
        }
      ],
      "trialIds": [
        "NCT07717814"
      ],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "ctg-nct07717814-v1"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "ctg-nct07717814-v1"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT07717814?a=1&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/maridebart-cafraglutide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/maridebart-cafraglutide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "ctg-nct07717814-v1"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "mazdutide",
      "canonicalUrl": "https://peptidescanner.com/peptides/mazdutide/",
      "name": "Mazdutide",
      "relatedNames": [
        "IBI362",
        "LY3305677"
      ],
      "topic": "Metabolic",
      "status": "investigational",
      "statusLabel": "Investigational",
      "summary": "A metabolic peptide candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.",
      "evidenceNote": "ClinicalTrials.gov lists a West China Hospital study as not yet recruiting, updated July 21, 2026.",
      "organizations": [
        {
          "name": "West China Hospital",
          "sourceIds": [
            "ctg-nct07718126-v1"
          ]
        }
      ],
      "trialIds": [
        "NCT07718126"
      ],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "ctg-nct07718126-v1"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "ctg-nct07718126-v1"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT07718126?a=1&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/mazdutide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/mazdutide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "ctg-nct07718126-v1"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "mots-c",
      "canonicalUrl": "https://peptidescanner.com/peptides/mots-c/",
      "name": "MOTS-c",
      "relatedNames": [
        "MOTS-C"
      ],
      "topic": "Safety records",
      "status": "safety-review",
      "statusLabel": "FDA compounding safety review",
      "summary": "A mitochondrial-derived peptide represented in FDA compounding-risk and advisory-committee records.",
      "evidenceNote": "FDA presented MOTS-c briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.",
      "organizations": [
        {
          "name": "U.S. Food and Drug Administration",
          "sourceIds": [
            "fda-bulk-peptide-risks",
            "fda-mots-c-briefing",
            "fda-pcac-peptide-meeting-2026"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-29",
      "correction": {
        "state": "updated",
        "notice": "We added FDA's dedicated briefing and advisory-committee meeting record, while preserving the pending and nonbinding nature of the review.",
        "publishedAt": "2026-07-29",
        "sourceIds": [
          "fda-mots-c-briefing",
          "fda-pcac-peptide-meeting-2026"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "fda-bulk-peptide-risks",
        "fda-mots-c-briefing",
        "fda-pcac-peptide-meeting-2026"
      ],
      "citations": [
        "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks",
        "https://www.fda.gov/media/193347/download",
        "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/mots-c/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/mots-c/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "updated",
            "notice": "We added FDA's dedicated briefing and advisory-committee meeting record, while preserving the pending and nonbinding nature of the review.",
            "publishedAt": "2026-07-29",
            "sourceIds": [
              "fda-mots-c-briefing",
              "fda-pcac-peptide-meeting-2026"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "octreotide",
      "canonicalUrl": "https://peptidescanner.com/peptides/octreotide/",
      "name": "Octreotide",
      "relatedNames": [
        "Octreotide acetate"
      ],
      "topic": "Endocrine",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A somatostatin analogue. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Octreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=387d7f8d-9762-4f6b-99e1-bdc50b8a1633&version=2"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/octreotide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/octreotide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "pemvidutide",
      "canonicalUrl": "https://peptidescanner.com/peptides/pemvidutide/",
      "name": "Pemvidutide",
      "relatedNames": [
        "ALT-801"
      ],
      "topic": "Metabolic",
      "status": "investigational",
      "statusLabel": "Investigational",
      "summary": "A glucagon/GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.",
      "evidenceNote": "ClinicalTrials.gov lists Altimmune's IMPACT study as completed, last updated May 18, 2026.",
      "organizations": [
        {
          "name": "Altimmune, Inc.",
          "sourceIds": [
            "ctg-nct05989711-v10"
          ]
        }
      ],
      "trialIds": [
        "NCT05989711"
      ],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "ctg-nct05989711-v10"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "ctg-nct05989711-v10"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT05989711?a=10&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/pemvidutide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/pemvidutide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "ctg-nct05989711-v10"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "petrelintide",
      "canonicalUrl": "https://peptidescanner.com/peptides/petrelintide/",
      "name": "Petrelintide",
      "relatedNames": [
        "ZP8396"
      ],
      "topic": "Metabolic",
      "status": "investigational",
      "statusLabel": "Investigational",
      "summary": "An amylin analogue candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.",
      "evidenceNote": "ClinicalTrials.gov lists a Roche-sponsored combination study as not yet recruiting, updated July 7, 2026.",
      "organizations": [
        {
          "name": "Hoffmann-La Roche",
          "sourceIds": [
            "ctg-nct07589686-v3"
          ]
        }
      ],
      "trialIds": [
        "NCT07589686"
      ],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "ctg-nct07589686-v3"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "ctg-nct07589686-v3"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT07589686?a=3&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/petrelintide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/petrelintide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "ctg-nct07589686-v3"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "plecanatide",
      "canonicalUrl": "https://peptidescanner.com/peptides/plecanatide/",
      "name": "Plecanatide",
      "relatedNames": [
        "Trulance"
      ],
      "topic": "Gastrointestinal",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A guanylate cyclase-C agonist peptide. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Plecanatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=fe2895bf-71a6-493a-b0ca-e06b2dfefc82&version=15"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/plecanatide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/plecanatide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "pramlintide",
      "canonicalUrl": "https://peptidescanner.com/peptides/pramlintide/",
      "name": "Pramlintide",
      "relatedNames": [
        "SymlinPen"
      ],
      "topic": "Metabolic",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "An amylin analogue. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Pramlintide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4aea30ff-eb0d-45c1-b114-3127966328ff&version=18"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/pramlintide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/pramlintide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "retatrutide",
      "canonicalUrl": "https://peptidescanner.com/peptides/retatrutide/",
      "name": "Retatrutide",
      "relatedNames": [
        "LY3437943"
      ],
      "topic": "Metabolic",
      "status": "investigational",
      "statusLabel": "Investigational",
      "summary": "A multi-receptor metabolic candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.",
      "evidenceNote": "ClinicalTrials.gov lists an Eli Lilly study as active, not recruiting, with a registry update posted July 20, 2026.",
      "organizations": [
        {
          "name": "Eli Lilly and Company",
          "sourceIds": [
            "ctg-nct06297603-v25"
          ]
        }
      ],
      "trialIds": [
        "NCT06297603"
      ],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "ctg-nct06297603-v25"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "ctg-nct06297603-v25"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT06297603?a=25&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/retatrutide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/retatrutide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "ctg-nct06297603-v25"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "semaglutide",
      "canonicalUrl": "https://peptidescanner.com/peptides/semaglutide/",
      "name": "Semaglutide",
      "relatedNames": [
        "Wegovy",
        "Ozempic",
        "Rybelsus"
      ],
      "topic": "Metabolic",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A GLP-1 receptor agonist. This profile cites a Wegovy label and an FDA notice.",
      "evidenceNote": "The cited DailyMed label identifies Semaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19"
          ]
        }
      ],
      "trialIds": [],
      "version": 3,
      "publishedAt": "2026-07-29",
      "correction": {
        "state": "updated",
        "notice": "We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.",
        "publishedAt": "2026-07-29",
        "sourceIds": [
          "fda-semaglutide-identity"
        ],
        "supersedesVersion": 2
      },
      "sourceIds": [
        "dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19",
        "fda-semaglutide-2026",
        "fda-semaglutide-identity"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=19",
        "https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide",
        "https://precision.fda.gov/uniisearch/srs/unii/53AXN4NNHX"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/semaglutide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/semaglutide/versions/2/",
          "publishedAt": "2026-07-27",
          "supersededAt": "2026-07-29",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19",
              "fda-semaglutide-2026"
            ],
            "supersedesVersion": 1
          }
        },
        {
          "version": 3,
          "canonicalUrl": "https://peptidescanner.com/peptides/semaglutide/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "updated",
            "notice": "We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.",
            "publishedAt": "2026-07-29",
            "sourceIds": [
              "fda-semaglutide-identity"
            ],
            "supersedesVersion": 2
          }
        }
      ]
    },
    {
      "slug": "semax",
      "canonicalUrl": "https://peptidescanner.com/peptides/semax/",
      "name": "Semax",
      "relatedNames": [],
      "topic": "Safety records",
      "status": "safety-review",
      "statusLabel": "FDA compounding safety review; final determination pending",
      "summary": "A synthetic peptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.",
      "evidenceNote": "FDA's Semax briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.",
      "organizations": [
        {
          "name": "U.S. Food and Drug Administration",
          "sourceIds": [
            "fda-semax-briefing",
            "fda-pcac-peptide-meeting-2026"
          ]
        }
      ],
      "trialIds": [],
      "version": 1,
      "publishedAt": "2026-07-29",
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "fda-semax-briefing",
        "fda-pcac-peptide-meeting-2026"
      ],
      "citations": [
        "https://www.fda.gov/media/193348/download",
        "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/semax/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "setmelanotide",
      "canonicalUrl": "https://peptidescanner.com/peptides/setmelanotide/",
      "name": "Setmelanotide",
      "relatedNames": [
        "Imcivree"
      ],
      "topic": "Rare disease",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A melanocortin-4 receptor agonist. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Setmelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9&version=14"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/setmelanotide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/setmelanotide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "survodutide",
      "canonicalUrl": "https://peptidescanner.com/peptides/survodutide/",
      "name": "Survodutide",
      "relatedNames": [
        "BI 456906"
      ],
      "topic": "Metabolic",
      "status": "investigational",
      "statusLabel": "Investigational",
      "summary": "A glucagon/GLP-1 receptor agonist candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.",
      "evidenceNote": "ClinicalTrials.gov lists a Boehringer Ingelheim study as active, not recruiting, updated July 22, 2026.",
      "organizations": [
        {
          "name": "Boehringer Ingelheim",
          "sourceIds": [
            "ctg-nct05202353-v50"
          ]
        }
      ],
      "trialIds": [
        "NCT05202353"
      ],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "ctg-nct05202353-v50"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "ctg-nct05202353-v50"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT05202353?a=50&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/survodutide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/survodutide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "ctg-nct05202353-v50"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "tb-500",
      "canonicalUrl": "https://peptidescanner.com/peptides/tb-500/",
      "name": "TB-500",
      "relatedNames": [
        "N-terminal acetylated 17-23 fragment of thymosin beta-4"
      ],
      "topic": "Safety records",
      "status": "safety-review",
      "statusLabel": "FDA compounding safety review; final determination pending",
      "summary": "A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.",
      "evidenceNote": "FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.",
      "organizations": [
        {
          "name": "U.S. Food and Drug Administration",
          "sourceIds": [
            "fda-tb-500-identity",
            "fda-tb-500-briefing",
            "fda-pcac-peptide-meeting-2026"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-29",
      "correction": {
        "state": "updated",
        "notice": "We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination.",
        "publishedAt": "2026-07-29",
        "sourceIds": [
          "fda-tb-500-briefing",
          "fda-pcac-peptide-meeting-2026"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "fda-tb-500-identity",
        "fda-tb-500-briefing",
        "fda-pcac-peptide-meeting-2026"
      ],
      "citations": [
        "https://precision.fda.gov/uniisearch/srs/unii/QHK6Z47GTG",
        "https://www.fda.gov/media/193349/download",
        "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/tb-500/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/tb-500/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "updated",
            "notice": "We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination.",
            "publishedAt": "2026-07-29",
            "sourceIds": [
              "fda-tb-500-briefing",
              "fda-pcac-peptide-meeting-2026"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "teriparatide",
      "canonicalUrl": "https://peptidescanner.com/peptides/teriparatide/",
      "name": "Teriparatide",
      "relatedNames": [],
      "topic": "Bone",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A parathyroid hormone analogue. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Teriparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=d77d40db-7f38-88eb-fd5d-4282f0642028&version=9"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/teriparatide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/teriparatide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "tesamorelin",
      "canonicalUrl": "https://peptidescanner.com/peptides/tesamorelin/",
      "name": "Tesamorelin",
      "relatedNames": [
        "Egrifta"
      ],
      "topic": "Endocrine",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A growth-hormone-releasing factor analogue. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Tesamorelin and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=3d783378-b02d-4f19-99dd-0fc91a042224&version=8"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/tesamorelin/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/tesamorelin/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "tirzepatide",
      "canonicalUrl": "https://peptidescanner.com/peptides/tirzepatide/",
      "name": "Tirzepatide",
      "relatedNames": [
        "Zepbound",
        "Mounjaro"
      ],
      "topic": "Metabolic",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A GIP and GLP-1 receptor agonist. This profile cites a Zepbound label and an FDA notice.",
      "evidenceNote": "The cited DailyMed label identifies Tirzepatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38"
          ]
        }
      ],
      "trialIds": [],
      "version": 3,
      "publishedAt": "2026-07-29",
      "correction": {
        "state": "updated",
        "notice": "We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.",
        "publishedAt": "2026-07-29",
        "sourceIds": [
          "fda-tirzepatide-identity"
        ],
        "supersedesVersion": 2
      },
      "sourceIds": [
        "dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38",
        "fda-tirzepatide-2023",
        "fda-tirzepatide-identity"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38",
        "https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management",
        "https://precision.fda.gov/uniisearch/srs/unii/OYN3CCI6QE"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/tirzepatide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/tirzepatide/versions/2/",
          "publishedAt": "2026-07-27",
          "supersededAt": "2026-07-29",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38",
              "fda-tirzepatide-2023"
            ],
            "supersedesVersion": 1
          }
        },
        {
          "version": 3,
          "canonicalUrl": "https://peptidescanner.com/peptides/tirzepatide/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "updated",
            "notice": "We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.",
            "publishedAt": "2026-07-29",
            "sourceIds": [
              "fda-tirzepatide-identity"
            ],
            "supersedesVersion": 2
          }
        }
      ]
    },
    {
      "slug": "vosoritide",
      "canonicalUrl": "https://peptidescanner.com/peptides/vosoritide/",
      "name": "Vosoritide",
      "relatedNames": [
        "Voxzogo"
      ],
      "topic": "Rare disease",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A C-type natriuretic peptide analogue. This profile cites a U.S. label record.",
      "evidenceNote": "The cited DailyMed label identifies Vosoritide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=228e8560-04a4-4bb1-a81f-29531a9e4d27&version=16"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/vosoritide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/vosoritide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    },
    {
      "slug": "ziconotide",
      "canonicalUrl": "https://peptidescanner.com/peptides/ziconotide/",
      "name": "Ziconotide",
      "relatedNames": [
        "Prialt"
      ],
      "topic": "Neurology",
      "status": "marketed",
      "statusLabel": "U.S. label record",
      "summary": "A synthetic peptide. This profile cites a U.S. intrathecal-drug label.",
      "evidenceNote": "The cited DailyMed label identifies Ziconotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.",
      "organizations": [
        {
          "name": "U.S. National Library of Medicine",
          "sourceIds": [
            "dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6"
          ]
        }
      ],
      "trialIds": [],
      "version": 2,
      "publishedAt": "2026-07-27",
      "correction": {
        "state": "updated",
        "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
        "publishedAt": "2026-07-27",
        "sourceIds": [
          "dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6"
        ],
        "supersedesVersion": 1
      },
      "sourceIds": [
        "dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6"
      ],
      "citations": [
        "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1&version=6"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/peptides/ziconotide/versions/1/",
          "publishedAt": "2026-07-22",
          "supersededAt": "2026-07-27",
          "correction": {
            "state": "none"
          }
        },
        {
          "version": 2,
          "canonicalUrl": "https://peptidescanner.com/peptides/ziconotide/",
          "publishedAt": "2026-07-27",
          "correction": {
            "state": "updated",
            "notice": "We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.",
            "publishedAt": "2026-07-27",
            "sourceIds": [
              "dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6"
            ],
            "supersedesVersion": 1
          }
        }
      ]
    }
  ],
  "updates": [
    {
      "slug": "fda-pcac-peptide-review-meeting",
      "canonicalUrl": "https://peptidescanner.com/stories/fda-pcac-peptide-review-meeting/",
      "title": "FDA committee met on seven peptide-related groups of bulk drug substances",
      "summary": "FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.",
      "domain": "Regulatory",
      "dateInSource": "2026-07-24",
      "sourceCheckedAt": "2026-07-29",
      "publishedAt": "2026-07-29",
      "peptideSlugs": [
        "bpc-157",
        "emideltide",
        "epitalon",
        "kpv",
        "mots-c",
        "semax",
        "tb-500"
      ],
      "paragraphs": [
        {
          "text": "FDA's meeting page groups the discussed bulk drug substances under BPC-157, emideltide, epitalon, KPV, MOTS-c, Semax, and TB-500 and lists free-base and acetate forms for each of those seven peptide-related groups.",
          "sourceIds": [
            "fda-pcac-peptide-meeting-2026"
          ]
        },
        {
          "text": "FDA's briefing documents say advisory-committee recommendations are nonbinding and that FDA will make final determinations only after completing the committee process and relevant reviews. This update reports the meeting, not a final FDA decision on any substance.",
          "sourceIds": [
            "fda-bpc-157-briefing",
            "fda-emideltide-briefing",
            "fda-epitalon-briefing",
            "fda-kpv-briefing",
            "fda-mots-c-briefing",
            "fda-semax-briefing",
            "fda-tb-500-briefing"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "fda-pcac-peptide-meeting-2026",
        "fda-bpc-157-briefing",
        "fda-emideltide-briefing",
        "fda-epitalon-briefing",
        "fda-kpv-briefing",
        "fda-mots-c-briefing",
        "fda-semax-briefing",
        "fda-tb-500-briefing"
      ],
      "citations": [
        "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026",
        "https://www.fda.gov/media/193343/download",
        "https://www.fda.gov/media/193344/download",
        "https://www.fda.gov/media/193345/download",
        "https://www.fda.gov/media/193346/download",
        "https://www.fda.gov/media/193347/download",
        "https://www.fda.gov/media/193348/download",
        "https://www.fda.gov/media/193349/download"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/fda-pcac-peptide-review-meeting/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "survodutide-liver-activity-study-updated",
      "canonicalUrl": "https://peptidescanner.com/stories/survodutide-liver-activity-study-updated/",
      "title": "Survodutide liver-activity study record updated",
      "summary": "ClinicalTrials.gov lists an active, not recruiting Survodutide study sponsored by Boehringer Ingelheim.",
      "domain": "Clinical trials",
      "dateInSource": "2026-07-22",
      "sourceCheckedAt": "2026-07-22",
      "publishedAt": "2026-07-22",
      "peptideSlugs": [
        "survodutide"
      ],
      "paragraphs": [
        {
          "text": "ClinicalTrials.gov lists the NCT05202353 record under Boehringer Ingelheim. Its overall recruitment status was shown as active, not recruiting when PeptideScanner reviewed the record.",
          "sourceIds": [
            "ctg-nct05202353-v50"
          ]
        },
        {
          "text": "The registry shows 2026-07-22 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome.",
          "sourceIds": [
            "ctg-nct05202353-v50"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "ctg-nct05202353-v50"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT05202353?a=50&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/survodutide-liver-activity-study-updated/",
          "publishedAt": "2026-07-22",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "maritide-bioavailability-study-updated",
      "canonicalUrl": "https://peptidescanner.com/stories/maritide-bioavailability-study-updated/",
      "title": "MariTide bioavailability study record updated",
      "summary": "ClinicalTrials.gov lists a completed Maridebart cafraglutide study sponsored by Amgen.",
      "domain": "Clinical trials",
      "dateInSource": "2026-07-21",
      "sourceCheckedAt": "2026-07-22",
      "publishedAt": "2026-07-22",
      "peptideSlugs": [
        "maridebart-cafraglutide"
      ],
      "paragraphs": [
        {
          "text": "ClinicalTrials.gov lists the NCT07717814 record under Amgen. Its overall recruitment status was shown as completed when PeptideScanner reviewed the record.",
          "sourceIds": [
            "ctg-nct07717814-v1"
          ]
        },
        {
          "text": "The registry shows 2026-07-21 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome.",
          "sourceIds": [
            "ctg-nct07717814-v1"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "ctg-nct07717814-v1"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT07717814?a=1&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/maritide-bioavailability-study-updated/",
          "publishedAt": "2026-07-22",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "mazdutide-liver-donor-study-posted",
      "canonicalUrl": "https://peptidescanner.com/stories/mazdutide-liver-donor-study-posted/",
      "title": "Mazdutide living-liver-donor study record posted",
      "summary": "ClinicalTrials.gov lists a Mazdutide study that is not yet recruiting sponsored by West China Hospital.",
      "domain": "Clinical trials",
      "dateInSource": "2026-07-21",
      "sourceCheckedAt": "2026-07-22",
      "publishedAt": "2026-07-22",
      "peptideSlugs": [
        "mazdutide"
      ],
      "paragraphs": [
        {
          "text": "ClinicalTrials.gov lists the NCT07718126 record under West China Hospital. Its overall recruitment status was shown as not yet recruiting when PeptideScanner reviewed the record.",
          "sourceIds": [
            "ctg-nct07718126-v1"
          ]
        },
        {
          "text": "The registry shows 2026-07-21 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome.",
          "sourceIds": [
            "ctg-nct07718126-v1"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "ctg-nct07718126-v1"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT07718126?a=1&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/mazdutide-liver-donor-study-posted/",
          "publishedAt": "2026-07-22",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "retatrutide-renal-impairment-study-updated",
      "canonicalUrl": "https://peptidescanner.com/stories/retatrutide-renal-impairment-study-updated/",
      "title": "Retatrutide renal-impairment study record updated",
      "summary": "ClinicalTrials.gov lists an active, not recruiting Retatrutide study sponsored by Eli Lilly and Company.",
      "domain": "Clinical trials",
      "dateInSource": "2026-07-20",
      "sourceCheckedAt": "2026-07-22",
      "publishedAt": "2026-07-22",
      "peptideSlugs": [
        "retatrutide"
      ],
      "paragraphs": [
        {
          "text": "ClinicalTrials.gov lists the NCT06297603 record under Eli Lilly and Company. Its overall recruitment status was shown as active, not recruiting when PeptideScanner reviewed the record.",
          "sourceIds": [
            "ctg-nct06297603-v25"
          ]
        },
        {
          "text": "The registry shows 2026-07-20 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome.",
          "sourceIds": [
            "ctg-nct06297603-v25"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "ctg-nct06297603-v25"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT06297603?a=25&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/retatrutide-renal-impairment-study-updated/",
          "publishedAt": "2026-07-22",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "cagrilintide-pediatric-study-updated",
      "canonicalUrl": "https://peptidescanner.com/stories/cagrilintide-pediatric-study-updated/",
      "title": "Cagrilintide pediatric study record updated",
      "summary": "ClinicalTrials.gov lists a recruiting Cagrilintide study sponsored by Novo Nordisk A/S.",
      "domain": "Clinical trials",
      "dateInSource": "2026-07-17",
      "sourceCheckedAt": "2026-07-22",
      "publishedAt": "2026-07-22",
      "peptideSlugs": [
        "cagrilintide"
      ],
      "paragraphs": [
        {
          "text": "ClinicalTrials.gov lists the NCT07253285 record under Novo Nordisk A/S. Its overall recruitment status was shown as recruiting when PeptideScanner reviewed the record.",
          "sourceIds": [
            "ctg-nct07253285-v5"
          ]
        },
        {
          "text": "The registry shows 2026-07-17 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome.",
          "sourceIds": [
            "ctg-nct07253285-v5"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "ctg-nct07253285-v5"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT07253285?a=5&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/cagrilintide-pediatric-study-updated/",
          "publishedAt": "2026-07-22",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "elamipretide-barth-syndrome-study-updated",
      "canonicalUrl": "https://peptidescanner.com/stories/elamipretide-barth-syndrome-study-updated/",
      "title": "Elamipretide Barth syndrome study record updated",
      "summary": "ClinicalTrials.gov lists a recruiting Elamipretide study sponsored by Stealth BioTherapeutics Inc.",
      "domain": "Clinical trials",
      "dateInSource": "2026-07-13",
      "sourceCheckedAt": "2026-07-22",
      "publishedAt": "2026-07-22",
      "peptideSlugs": [
        "elamipretide"
      ],
      "paragraphs": [
        {
          "text": "ClinicalTrials.gov lists the NCT07531251 record under Stealth BioTherapeutics Inc. Its overall recruitment status was shown as recruiting when PeptideScanner reviewed the record.",
          "sourceIds": [
            "ctg-nct07531251-v4"
          ]
        },
        {
          "text": "The registry shows 2026-07-13 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome.",
          "sourceIds": [
            "ctg-nct07531251-v4"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "ctg-nct07531251-v4"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT07531251?a=4&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/elamipretide-barth-syndrome-study-updated/",
          "publishedAt": "2026-07-22",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "petrelintide-combination-study-posted",
      "canonicalUrl": "https://peptidescanner.com/stories/petrelintide-combination-study-posted/",
      "title": "Petrelintide combination study record posted",
      "summary": "ClinicalTrials.gov lists a Petrelintide study that is not yet recruiting sponsored by Hoffmann-La Roche.",
      "domain": "Clinical trials",
      "dateInSource": "2026-07-07",
      "sourceCheckedAt": "2026-07-22",
      "publishedAt": "2026-07-22",
      "peptideSlugs": [
        "petrelintide"
      ],
      "paragraphs": [
        {
          "text": "ClinicalTrials.gov lists the NCT07589686 record under Hoffmann-La Roche. Its overall recruitment status was shown as not yet recruiting when PeptideScanner reviewed the record.",
          "sourceIds": [
            "ctg-nct07589686-v3"
          ]
        },
        {
          "text": "The registry shows 2026-07-07 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome.",
          "sourceIds": [
            "ctg-nct07589686-v3"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "ctg-nct07589686-v3"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT07589686?a=3&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/petrelintide-combination-study-posted/",
          "publishedAt": "2026-07-22",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "fda-unapproved-glp1-concerns-record",
      "canonicalUrl": "https://peptidescanner.com/stories/fda-unapproved-glp1-concerns-record/",
      "title": "FDA details concerns with unapproved GLP-1 products",
      "summary": "FDA's public page describes agency concerns and actions involving unapproved versions of semaglutide and tirzepatide, with adverse-event information dated May 31, 2026.",
      "domain": "Safety",
      "dateInSource": "2026-05-31",
      "sourceCheckedAt": "2026-07-29",
      "publishedAt": "2026-07-29",
      "peptideSlugs": [
        "semaglutide",
        "tirzepatide"
      ],
      "paragraphs": [
        {
          "text": "FDA's page distinguishes FDA-approved products from unapproved versions and compiles agency concerns, enforcement activity, reported quality problems, and adverse-event information dated May 31, 2026.",
          "sourceIds": [
            "fda-unapproved-glp1-concerns-2026"
          ]
        },
        {
          "text": "This update attributes those statements to FDA and does not evaluate a product, pharmacy, treatment choice, or individual report. It also does not turn FDA's examples into a complete market survey.",
          "sourceIds": [
            "fda-unapproved-glp1-concerns-2026"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "fda-unapproved-glp1-concerns-2026"
      ],
      "citations": [
        "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/fda-unapproved-glp1-concerns-record/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "pemvidutide-impact-study-updated",
      "canonicalUrl": "https://peptidescanner.com/stories/pemvidutide-impact-study-updated/",
      "title": "Pemvidutide IMPACT study record updated",
      "summary": "ClinicalTrials.gov lists a completed Pemvidutide study sponsored by Altimmune, Inc.",
      "domain": "Clinical trials",
      "dateInSource": "2026-05-18",
      "sourceCheckedAt": "2026-07-22",
      "publishedAt": "2026-07-22",
      "peptideSlugs": [
        "pemvidutide"
      ],
      "paragraphs": [
        {
          "text": "ClinicalTrials.gov lists the NCT05989711 record under Altimmune, Inc. Its overall recruitment status was shown as completed when PeptideScanner reviewed the record.",
          "sourceIds": [
            "ctg-nct05989711-v10"
          ]
        },
        {
          "text": "The registry shows 2026-05-18 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome.",
          "sourceIds": [
            "ctg-nct05989711-v10"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "ctg-nct05989711-v10"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT05989711?a=10&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/pemvidutide-impact-study-updated/",
          "publishedAt": "2026-07-22",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "fda-glp1-503b-bulks-list-proposal",
      "canonicalUrl": "https://peptidescanner.com/stories/fda-glp1-503b-bulks-list-proposal/",
      "title": "FDA proposes excluding three GLP-1 ingredients from the 503B bulks list",
      "summary": "FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding.",
      "domain": "Regulatory",
      "dateInSource": "2026-04-30",
      "sourceCheckedAt": "2026-07-29",
      "publishedAt": "2026-07-29",
      "peptideSlugs": [
        "semaglutide",
        "tirzepatide",
        "liraglutide"
      ],
      "paragraphs": [
        {
          "text": "FDA announced a proposal concerning semaglutide, tirzepatide, and liraglutide and the 503B bulks list used by outsourcing facilities.",
          "sourceIds": [
            "fda-glp1-bulks-proposal-2026"
          ]
        },
        {
          "text": "The agency action is a proposal, not a final rule or a statement that all compounding circumstances are identical. This update preserves that procedural distinction.",
          "sourceIds": [
            "fda-glp1-bulks-proposal-2026"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "fda-glp1-bulks-proposal-2026"
      ],
      "citations": [
        "https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/fda-glp1-503b-bulks-list-proposal/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "fda-gram-peptides-warning-letter",
      "canonicalUrl": "https://peptidescanner.com/stories/fda-gram-peptides-warning-letter/",
      "title": "FDA warning letter names retatrutide and tirzepatide products",
      "summary": "FDA issued a warning letter to Gram Peptides that describes the agency's findings about products marketed with retatrutide and tirzepatide.",
      "domain": "Regulatory",
      "dateInSource": "2026-03-31",
      "sourceCheckedAt": "2026-07-29",
      "publishedAt": "2026-07-29",
      "peptideSlugs": [
        "retatrutide",
        "tirzepatide"
      ],
      "paragraphs": [
        {
          "text": "The cited FDA warning letter identifies products marketed with retatrutide and tirzepatide and records the agency's stated regulatory findings concerning the recipient.",
          "sourceIds": [
            "fda-gram-peptides-warning-letter-2026"
          ]
        },
        {
          "text": "A warning letter records FDA's position and requested response at the time it was issued. This update does not generalize those findings to unrelated products or report a later resolution.",
          "sourceIds": [
            "fda-gram-peptides-warning-letter-2026"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "fda-gram-peptides-warning-letter-2026"
      ],
      "citations": [
        "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/fda-gram-peptides-warning-letter/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "fda-higher-dose-semaglutide-approval",
      "canonicalUrl": "https://peptidescanner.com/stories/fda-higher-dose-semaglutide-approval/",
      "title": "FDA announces approval of a higher-dose semaglutide product",
      "summary": "FDA announced approval of a higher-dose Wegovy product, adding a regulatory event to the semaglutide profile's selected official records.",
      "domain": "Regulatory",
      "dateInSource": "2026-03-19",
      "sourceCheckedAt": "2026-07-22",
      "publishedAt": "2026-07-29",
      "peptideSlugs": [
        "semaglutide"
      ],
      "paragraphs": [
        {
          "text": "FDA's announcement describes its approval of a higher-dose Wegovy product containing semaglutide under the agency's national-priority voucher program.",
          "sourceIds": [
            "fda-semaglutide-2026"
          ]
        },
        {
          "text": "This update reports the regulatory action and links to FDA's announcement. It does not restate indications, compare products, or provide treatment guidance.",
          "sourceIds": [
            "fda-semaglutide-2026"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "fda-semaglutide-2026"
      ],
      "citations": [
        "https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/fda-higher-dose-semaglutide-approval/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "bpc-157-hamstring-study-posted",
      "canonicalUrl": "https://peptidescanner.com/stories/bpc-157-hamstring-study-posted/",
      "title": "BPC-157 hamstring study appears in trial registry",
      "summary": "ClinicalTrials.gov lists a recruiting BPC-157 study sponsored by Hudson Biotech.",
      "domain": "Clinical trials",
      "dateInSource": "2026-02-27",
      "sourceCheckedAt": "2026-07-22",
      "publishedAt": "2026-07-22",
      "peptideSlugs": [
        "bpc-157"
      ],
      "paragraphs": [
        {
          "text": "ClinicalTrials.gov lists the NCT07437547 record under Hudson Biotech. Its overall recruitment status was shown as recruiting when PeptideScanner reviewed the record.",
          "sourceIds": [
            "ctg-nct07437547-v1"
          ]
        },
        {
          "text": "The registry shows 2026-02-27 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome.",
          "sourceIds": [
            "ctg-nct07437547-v1"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "ctg-nct07437547-v1"
      ],
      "citations": [
        "https://clinicaltrials.gov/study/NCT07437547?a=1&tab=history"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/bpc-157-hamstring-study-posted/",
          "publishedAt": "2026-07-22",
          "correction": {
            "state": "none"
          }
        }
      ]
    },
    {
      "slug": "fda-glp1-label-warning-removal-request",
      "canonicalUrl": "https://peptidescanner.com/stories/fda-glp1-label-warning-removal-request/",
      "title": "FDA requests removal of a warning from certain GLP-1 drug labels",
      "summary": "FDA asked manufacturers to remove suicidal behavior and ideation warning language from certain semaglutide, tirzepatide, and liraglutide labels.",
      "domain": "Safety",
      "dateInSource": "2026-01-13",
      "sourceCheckedAt": "2026-07-29",
      "publishedAt": "2026-07-29",
      "peptideSlugs": [
        "semaglutide",
        "tirzepatide",
        "liraglutide"
      ],
      "paragraphs": [
        {
          "text": "FDA's communication says the agency requested that manufacturers remove suicidal behavior and ideation warning language from the labels of certain GLP-1 receptor agonist medicines.",
          "sourceIds": [
            "fda-glp1-label-warning-request-2026"
          ]
        },
        {
          "text": "The FDA communication names Wegovy, Zepbound, and Saxenda. This update reports the agency's labeling request and does not provide an individualized interpretation of safety.",
          "sourceIds": [
            "fda-glp1-label-warning-request-2026"
          ]
        }
      ],
      "version": 1,
      "correction": {
        "state": "none"
      },
      "sourceIds": [
        "fda-glp1-label-warning-request-2026"
      ],
      "citations": [
        "https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp"
      ],
      "versions": [
        {
          "version": 1,
          "canonicalUrl": "https://peptidescanner.com/stories/fda-glp1-label-warning-removal-request/",
          "publishedAt": "2026-07-29",
          "correction": {
            "state": "none"
          }
        }
      ]
    }
  ],
  "sources": [
    {
      "id": "ctg-nct05202353-v50",
      "name": "ClinicalTrials.gov",
      "sourceClass": "A",
      "title": "BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver · record history version 50 · last update posted 2026-07-22",
      "url": "https://clinicaltrials.gov/study/NCT05202353?a=50&tab=history",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "ctg-nct05989711-v10",
      "name": "ClinicalTrials.gov",
      "sourceClass": "A",
      "title": "IMPACT: Pemvidutide in Participants With NASH · record history version 10 · last update posted 2026-05-18",
      "url": "https://clinicaltrials.gov/study/NCT05989711?a=10&tab=history",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "ctg-nct06049329-v6",
      "name": "ClinicalTrials.gov",
      "sourceClass": "A",
      "title": "Oral Amycretin in Japanese Men With Obesity · record history version 6 · last update posted 2025-03-05",
      "url": "https://clinicaltrials.gov/study/NCT06049329?a=6&tab=history",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "ctg-nct06297603-v25",
      "name": "ClinicalTrials.gov",
      "sourceClass": "A",
      "title": "Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20",
      "url": "https://clinicaltrials.gov/study/NCT06297603?a=25&tab=history",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "ctg-nct07253285-v5",
      "name": "ClinicalTrials.gov",
      "sourceClass": "A",
      "title": "Cagrilintide and CagriSema in Children and Adolescents With Excess Body Weight · record history version 5 · last update posted 2026-07-17",
      "url": "https://clinicaltrials.gov/study/NCT07253285?a=5&tab=history",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "ctg-nct07437547-v1",
      "name": "ClinicalTrials.gov",
      "sourceClass": "A",
      "title": "BPC 157 for Acute Hamstring Muscle Strain Repair · record history version 1 · last update posted 2026-02-27",
      "url": "https://clinicaltrials.gov/study/NCT07437547?a=1&tab=history",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "ctg-nct07531251-v4",
      "name": "ClinicalTrials.gov",
      "sourceClass": "A",
      "title": "4TAZPower: Elamipretide in Participants With Barth Syndrome · record history version 4 · last update posted 2026-07-13",
      "url": "https://clinicaltrials.gov/study/NCT07531251?a=4&tab=history",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "ctg-nct07589686-v3",
      "name": "ClinicalTrials.gov",
      "sourceClass": "A",
      "title": "Petrelintide With Enicepatide in Adults With Obesity or Overweight · record history version 3 · last update posted 2026-07-07",
      "url": "https://clinicaltrials.gov/study/NCT07589686?a=3&tab=history",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "ctg-nct07717814-v1",
      "name": "ClinicalTrials.gov",
      "sourceClass": "A",
      "title": "Bioavailability of AMG 133 in Participants With Overweight or Obesity · record history version 1 · last update posted 2026-07-21",
      "url": "https://clinicaltrials.gov/study/NCT07717814?a=1&tab=history",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "ctg-nct07718126-v1",
      "name": "ClinicalTrials.gov",
      "sourceClass": "A",
      "title": "Pre-hepatectomy Rehabilitation in Living Liver Donors With Mazdutide · record history version 1 · last update posted 2026-07-21",
      "url": "https://clinicaltrials.gov/study/NCT07718126?a=1&tab=history",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "TYMLOS (abaloparatide) injection, solution · SPL version 18 · published 2025-04-11",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=18",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "SCENESSE (afamelanotide) implant · SPL version 11 · published 2026-05-13",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=94f53286-11dd-7fbb-e053-2a95a90a7c48&version=11",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "VYLEESI (bremelanotide) injection · SPL version 1 · published 2025-11-18",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf&version=1",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "TRULICITY (dulaglutide) injection, solution · SPL version 60 · published 2026-03-25",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=463050bd-2b1c-40f5-b3c3-0a04bb433309&version=60",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "Exenatide injection · SPL version 17 · published 2026-06-30",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=e6cb5c8f-e97f-4a6a-95a4-939fd2393949&version=17",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "GVOKE VIALDX (glucagon) injection, solution · SPL version 2 · published 2026-07-09",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=359982a8-ec5c-4927-8c0f-89771e0f942b&version=2",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "LANGLARA (insulin glargine-aldy) injection, solution · SPL version 5 · published 2026-07-08",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=5328761e-59d3-ca7a-e063-6394a90ae810&version=5",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "Lanreotide acetate injection · SPL version 3 · published 2025-06-02",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=2892b4c3-0329-4d29-97ff-3b45283bbab1&version=3",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "Leuprolide acetate kit · SPL version 10 · published 2026-07-06",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4838c674-044e-46b2-81e7-c691b99d8fa5&version=10",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "LINZESS (linaclotide) capsule · SPL version 39 · published 2026-06-01",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=09beda19-56d6-4a56-afdc-9a77b70b2ef3&version=39",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "Liraglutide injection, solution · SPL version 6 · published 2026-07-14",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=22c86976-9657-4dd0-8fff-0c3f3f08357c&version=6",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "SOLIQUA 100/33 (insulin glargine and lixisenatide) injection · SPL version 25 · published 2026-03-20",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=25",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "Octreotide acetate injection, solution · SPL version 2 · published 2026-02-02",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=387d7f8d-9762-4f6b-99e1-bdc50b8a1633&version=2",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "TRULANCE (plecanatide) tablet · SPL version 15 · published 2024-04-05",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=fe2895bf-71a6-493a-b0ca-e06b2dfefc82&version=15",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "SYMLINPEN (pramlintide acetate) injection · SPL version 18 · published 2024-08-20",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4aea30ff-eb0d-45c1-b114-3127966328ff&version=18",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=19",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "IMCIVREE (setmelanotide) solution · SPL version 14 · published 2026-04-02",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9&version=14",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "Teriparatide injection, solution · SPL version 9 · published 2026-06-30",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=d77d40db-7f38-88eb-fd5d-4282f0642028&version=9",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "EGRIFTA SV (tesamorelin) kit · SPL version 8 · published 2026-01-02",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=3d783378-b02d-4f19-99dd-0fc91a042224&version=8",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "ZEPBOUND (tirzepatide) injection · SPL version 38 · published 2026-05-06",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "VOXZOGO (vosoritide) kit · SPL version 16 · published 2025-11-26",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=228e8560-04a4-4bb1-a81f-29531a9e4d27&version=16",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6",
      "name": "DailyMed · U.S. National Library of Medicine",
      "sourceClass": "A",
      "title": "PRIALT (ziconotide acetate) injection, solution · SPL version 6 · published 2025-07-14",
      "url": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1&version=6",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "fda-bulk-peptide-risks",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "Certain bulk drug substances for use in compounding that may present significant safety risks",
      "url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-ghk-cu-503a-2026",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "503A bulk drug substances under evaluation · GHK-Cu except injectable routes · updated May 14, 2026",
      "url": "https://www.fda.gov/media/94155/download?attachment",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "doj-unapproved-peptide-enforcement",
      "name": "U.S. Department of Justice",
      "sourceClass": "A",
      "title": "Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs",
      "url": "https://www.justice.gov/usao-edky/pr/nicholasville-compounding-pharmacy-and-its-owner-plead-guilty-unlawful-distribution",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "fda-bpc-157-briefing",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA briefing document for BPC-157-related bulk drug substances",
      "url": "https://www.fda.gov/media/193343/download",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-tb-500-identity",
      "name": "FDA Global Substance Registration System",
      "sourceClass": "A",
      "title": "TB-500 substance identity record",
      "url": "https://precision.fda.gov/uniisearch/srs/unii/QHK6Z47GTG",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-semaglutide-2026",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA approves higher-dose semaglutide",
      "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "fda-tirzepatide-2023",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA approves tirzepatide for chronic weight management",
      "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management",
      "verifiedAt": "2026-07-22"
    },
    {
      "id": "fda-pcac-peptide-meeting-2026",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting",
      "url": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-emideltide-briefing",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA briefing document for emideltide (DSIP) (free base) and emideltide acetate",
      "url": "https://www.fda.gov/media/193344/download",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-epitalon-briefing",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA briefing document for epitalon",
      "url": "https://www.fda.gov/media/193345/download",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-kpv-briefing",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA briefing document for KPV",
      "url": "https://www.fda.gov/media/193346/download",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-mots-c-briefing",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA briefing document for MOTS-c",
      "url": "https://www.fda.gov/media/193347/download",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-semax-briefing",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA briefing document for Semax",
      "url": "https://www.fda.gov/media/193348/download",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-tb-500-briefing",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA briefing document for TB-500",
      "url": "https://www.fda.gov/media/193349/download",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-semaglutide-identity",
      "name": "FDA Global Substance Registration System",
      "sourceClass": "A",
      "title": "Semaglutide substance identity record",
      "url": "https://precision.fda.gov/uniisearch/srs/unii/53AXN4NNHX",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-tirzepatide-identity",
      "name": "FDA Global Substance Registration System",
      "sourceClass": "A",
      "title": "Tirzepatide substance identity record",
      "url": "https://precision.fda.gov/uniisearch/srs/unii/OYN3CCI6QE",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-bremelanotide-identity",
      "name": "FDA Global Substance Registration System",
      "sourceClass": "A",
      "title": "Bremelanotide substance identity record",
      "url": "https://precision.fda.gov/uniisearch/srs/unii/PV2WI7495P",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-ghk-cu-identity",
      "name": "FDA Global Substance Registration System",
      "sourceClass": "A",
      "title": "Copper tripeptide-1 substance identity record",
      "url": "https://precision.fda.gov/uniisearch/srs/unii/6BJQ43T1I9",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-glp1-bulks-proposal-2026",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list",
      "url": "https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-glp1-label-warning-request-2026",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels",
      "url": "https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-unapproved-glp1-concerns-2026",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA concerns with unapproved GLP-1 drugs used for weight loss",
      "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss",
      "verifiedAt": "2026-07-29"
    },
    {
      "id": "fda-gram-peptides-warning-letter-2026",
      "name": "U.S. Food and Drug Administration",
      "sourceClass": "A",
      "title": "FDA warning letter to Gram Peptides",
      "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026",
      "verifiedAt": "2026-07-29"
    }
  ]
}